World Congress of Neuropsychopharmacology (CINP)

Chair: Prof. Kazutaka Ikeda, Tokyo Metropolitan Institute of Medical Science, Japan

Description: As a world-renowned genius and the world’s first nonbinary and openly transgender cabinet member, Taiwan’s Digital Minister Audrey Tang successfully applies the technology in the COVID-19 prevention in Taiwan. She develops digital social innovation tools to help Taiwan health and disease control government officials efficiently and quickly track and control the spread of the virus. At the 33rd CINP world congress of neuropsychopharmacology, Minister Tang will have a brilliant conversation with CINP President Professor Pierre Blier. Topics will include the application of technology in mental health, the digital psychiatry, and the next-generation psychiatry in a virtual world. Let’s join them together online and in Taipei.

Plenary 4: Dr. Hailan Hu, Zhejiang University, China

Details: Saturday, June 11, 14:30 - 15:30 (GMT+8)

Speaker: Dr. Hailan Hu, Zhejiang University, China

Chair: Prof. Gabriella Gobbi, McGill University, Montreal, Canada

Description: Ketamine, the N-methyl-D-aspartate receptor (NMDAR) antagonist, has revolutionized depression treatment because of its robust, rapid and sustained antidepressant effects. Recently, it was discovered that ketamine inhibits the NMDAR-dependent burst firing of the brain’s anti-reward center, the lateral habenula (LHb). By silencing the LHb bursts, ketamine can disinhibit the aminergic reward circuits downstream of LHb to exert its rapid antidepressant effects.

However, at least three key questions have remained unaddressed. Firstly, does blockade of LHb burst firing contribute to ketamine’s sustained antidepressant effects? Despite of its rapid metabolic half-life (3 h in human and 13 min in mice), the antidepressant effects of a single application of ketamine can last for 3～14 d in humans and for at least 24 h in mouse models of depression. It will be clinically important to understand to what extent ketamine’s local action in the LHb contributes to its sustained effects. Secondly, given that NMDARs are ubiquitously expressed, which specific brain region is the direct target of ketamine? It will be important to distinguish the primary versus the secondary targets. Thirdly, will a drug targeting the same cellular/circuit mechanism of ketamine have similar antidepressant effects? More specifically, since LHb burst firing requires the synergistic action of both NMDARs and the T-type calcium channel (T-VSCC), can T-VSCC inhibitors be antidepressant?

In this talk, I will present our ongoing efforts in addressing these three urgent questions, which will hopefully illuminate a unified theory on ketamine’s mode of action and inspire new treatment strategies for depression.

Plenary 5: Dr. Edward Bullmore, University of Cambridge, United Kingdom

Title: Inflammation and Depression: Questions of Causality

Details: Saturday, June 11, 19:45 - 20:45 (GMT+8)

Speaker: Dr. Edward Bullmore, University of Cambridge, United Kingdom

Chair: Dr. John Krystal, Yale School of Medicine, USA

Description: Inflammation is robustly associated with depression and other mental health disorders. However, there are many open questions about the causal relationships that might explain the increasing mass of largely correlational findings. I will review several approaches to causality in the context of human research, including neuroimaging studies, meta-analyses of anti-depressant effects of anti-inflammatory drugs, and epigenetic activation of GWAS variants for risks of mental health disorders. I will also explore the hypothetical model that early life adversity and other social stressors could perturb developmental trajectories of the central nervous system and the peripheral immune system, leading to long-term changes in vulnerability to depression and other health disorders in adult life.

Plenary 6: Dr. Serena Pudich, Yale University, United States

Details: Sunday, June 12, 21:00 - 22:00 (GMT+8)

Speaker: Dr. Serena Pudich, Yale University, United States

Chair: Dr. John Krystal, Yale School of Medicine, USA

Description:
Background
During acute COVID-19, patients can experience ischemic cerebrovascular disorders, encephalopathy, and prolonged unconsciousness and altered mental states, including psychosis and delirium. Some individuals also develop a loss of smell and taste, myalgias and fatigue, or neuromuscular disorders. Many patients also experience post-acute COVID neurologic and psychiatric issues. These include prolonged symptoms of fatigue, memory concentration disorder, headache, pain, insomnia, anxiety, and depression.

Aims & Objectives
This talk will cover neurologic reports in acute COVID-19, existing knowledge regarding acute COVID-19 neuropathogenesis, and describe the clinical syndromes and explore potential mechanisms of nervous system Long COVID.

Methods
The speaker will review and critically interpret existing published literature. She will also draw upon her clinical observations and experiences caring for patients with COVID-19 and acute or lingering nervous system consequences. Finally, she will present unpublished data from her group’s investigation into the pathophysiology of Long COVID.

Results
At the end of the talk, the audience should be able to identify the clinical and pathophysiologic effects of SARS-CoV-2 in the nervous system during acute COVID-19, focusing on immunopathogenesis and neuronal injury. The audience will also be able to describe the hypotheses regarding potential underlying mechanisms of nervous system Long COVID, or post-acute sequelae of COVID-19, and recognize that lingering nervous system effects can occur in patients who experienced mild forms of COVID-19.

Discussion
The presentation will conclude with a discussion of future research gaps and priorities particularly with regard to long term neurologic and neuropsychiatric complications post-COVID-19.

Plenary 7: Dr. Tom Insel, National Institutes of Health, United States

Details: Monday, June 13, 3:30 - 4:30 (GMT+8)

Speaker: Dr. Tom Insel, National Institutes of Health, United States

Chair: Prof. Joseph Zohar, Chaim Sheba Medical Center, Israel

Description: Most of us have embarked on careers in neuropharmacology because we want to develop better treatments for people with mental illness and ultimately contribute to public health. Arguably the last five decades have been a golden era for neuropharmacology with a broad range of compounds (as well as psychological and neuromodulatory interventions) developed for mood, anxiety, and psychotic disorders. With so much progress in science, why have we made so little progress in outcomes for people with mental illness, especially those with serious mental illness? Why have we failed to reduce death and disability? Our usual explanations (lack of treatments, lack of knowledge, lack of providers, stigma) are not sufficient answers to this question. We face a mental health crisis not from a failure of research or insufficient workforce but from a broken mental health care system. Fixing the care system through better engagement, quality, and accountability will provide more immediate solutions, including some that can be delivered via technology. In 2022, we can achieve better outcomes from better care, using the treatments we have today. But to close the outcome gap, we need to understand that mental health is not simply a product of mental health care. Indeed, health care explains a relatively small fraction of health outcomes. This presentation will reframe the mental health crisis as more than a healthcare crisis, reminding us that we will always need better treatments but our immediate call to action is to use the treatments we have more effectively.

Meet The Expert Sessions

MTE01: Prof. Joseph Zohar, Chaim Sheba Medical Center, Israel

Title: ENCP Meet the Expert NbN

Details: Friday, June 10, 10:45 - 11:45 (GMT+8)

Speaker: Prof. Joseph Zohar, Chaim Sheba Medical Center, Israel

Description: The current disease-based nomenclature of psychotropics medications does not reflect contemporary knowledge, nor does it appropriately inform the clinician about rational neuroscience-based prescribing. Moreover, it is confusing for the patients as very often we prescribe “antidepressants” for anxiety disorders or “second-generation antipsychotics” to depressed patients who show no evidence of psychosis. Five major international neuropsychopharmacological scientific organizations joined forces together, in 2008, to create new nomenclature. These organizations are: ECNP, ACNP, AsCNP, CINP and IUPHAR.

The mission was:
- To provide a pharmacologically-driven (rather than indication-based nomenclature).
- To expand our toolbox by pointing out the relevant mechanism (via pharmacology and mode of action).
- To help clinicians to make informed choices when they are trying to figure out what would be the next “pharmacological step”.
- To decrease stigma and enhance adherence by a naming system that lays out the rationale for selecting a specific psychotropic.

Currently, NbN has been downloaded close to 100,000 psychiatrists worldwide and has been endorsed by many organizations including APA, EPA, DGPPN, JSPN, and SEP to name a few. It is also a part of major textbook of psychiatry including Oxford textbook of psychiatry, the next edition of Kaplan & Sadock textbook of psychiatry and more. NbN reflects current knowledge and understanding about the targeted neurotransmitters/molecules/system being modified + mode/ mechanism of action and includes 147 compounds that cover the vast majority of psychotropics used worldwide. In this session we will explain the concept and will do live presentation of NbN apps. (IOS: NbN3, NbNca ; Android: NbN3, NbNca).

MTE02: Prof. Tung Ping Su, Department of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan

Details: Saturday, June 11, 13:15 - 14:15 (GMT+8)

Speaker: Prof. Tung Ping Su, Department of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan

Description: Professor Tung-Ping Su has devoted himself to the treatment and research of treatment-resistant depression (TRD) since he returned to Taiwan from the NIMH in the United States in 1996. In Taiwan, he completed the first randomized, double-blind, sham-controlled trial of rTMS in patients with TRD in 2005. He further completed the first randomized, double-blind, placebo-controlled trial of low-dose ketamine infusion in patients with TRD in 2017. His clinical and research career represents the history of novel treatments for TRD in Taiwan. Today, he will talk about the past, present and future of TRD treatment.

MTE03: Prof. Pierre Blier, University of Ottawa Institute of Mental Health Research, Canada

Details: Monday, June 13, 00:15 - 01:15 (GMT+8)

Speaker: Prof. Pierre Blier, University of Ottawa Institute of Mental Health Research, Canada

Description: In this workshop, participants will be presented with the various medications that can be used and how to choose the potentially most useful and better-tolerated ones for specific patients. The main interactions with other medications used to treat co-morbidities will be described. Emphasis will be concentrated on cases of treatment resistance and how to devise comprehensive treatment plans. Participants will be encouraged throughout to ask questions and volunteer cases they are currently having difficulties to manage.

Learn More About CINP 2022’s Plenary Speakers

The CINP International Scientific Programme Committee is pleased to announce the following plenary speakers for the 2022 CINP Hybrid World Congress.


MINISTER AUDREY TANG
DIGITAL MINISTER, TAIWAN


DR. EDWARD BULLMORE
PROFESSOR OF PSYCHIATRY AND CLINICAL DIRECTOR, BEHAVIOURAL & CLINICAL NEUROSCIENCE INSTITUTE, UNIVERSITY OF CAMBRIDGE, UNITED KINGDOM


PROF. FRANCESCO BENEDETTI
UNIVERSITY VITA-SALUTE SAN RAFFAELE, MILANO


DR. HAILAN HU
PROFESSOR AND DIRECTOR OF THE SCHOOL OF BRAIN SCIENCE AND BRAIN MEDICINE, ZHEJIANG UNIVERSITY, CHINA


PROF. MASASHI YANAGISAWA
THE UNIVERSITY OF TSUKUBA, JAPAN


DR. SERENA PUDICH
PROFESSOR OF NEUROLOGY AND CHIEF, DIVISION OF NEUROLOGICAL INFECTIONS AND GLOBAL NEUROLOGY, YALE UNIVERSITY, UNITED STATES


DR. TOM INSEL
NATIONAL INSTITUTES OF HEALTH, UNITED STATES

What is a Hybrid Meeting?

The CINP 2022 Hybrid World Congress will be an event that combines delivery, participation, and interaction for virtual and in-person audiences. 
We can’t wait to meet with those who are able to travel to Taiwan at the conference venue between 9 - 13 June 2022. And by utilizing the latest technology to live-stream presentations to our virtual audience, we will provide opportunities for all attendees to engage with the scientific content, network with each other, and experience our first hybrid event.

Earn CME Accreditation at the 2022 CINP World Congress

Earn CME Accreditation at the 2022 CINP World Congress


We are pleased to announce that the 33rd CINP Hybrid World Congress of Neuropsychopharmacology, held from 9 to 13 June 2022 has been accredited by European Accreditation Committee in CNS (EACIC).

There will be a total number of 22 CME credits available for this congress.

How to Obtain CME Credits
Participants requesting CME credits are required to complete the online evaluation form on the EACIC website www.eacic.eu.
Please follow the below steps to receive your CME Certificate.

1. Go to the EACIC website www.eacic.eu
2. Click on “CLAIM YOUR CME CREDITS”
3. Choose the option “I AM ALREADY REGISTERED” or “I AM NOT REGISTERED”
4. The Event Code for this event is CINP2022
5. Log on or register
6. Complete the online evaluation form
7. Press “save”
8. Your CME certificate will be automatically emailed to the address provided
   This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the University of Ottawa’s Office of Continuing Professional Development. You may claim a maximum of 22,00 hours (credits are automatically calculated).

The deadline to complete the evaluation form is 13 September 2022.

If you have any enquiries, please contact cinp2022-program@cinp.org.

Presenter Resources

Download Resources

Download Presentation Slide Template
Download Background Option 1
Download Background Option 2
Download Background Option 3

Submissions

Oral Presentation Upload (MP4 format only)
Poster Presentation upload (MP4 or PDF format only)

Important Deadlines

• Presenting Author Registration Deadline April 15, 2022
• Deadline for Title/Authorship Changes April 15, 2022
• Recording Appointment (Invited Speakers & Featured Oral) May 2 – 20, 2022
• Self-Recorded Video Presentation Submission Due (Oral) May 20, 2022
• Poster Presentation / Self-Recorded Audio Presentation Submission Due (Poster) May 20, 2022

Presentation Submission

A link to upload your presentation or poster along with your final program number will be emailed to the presenting author by April 30, 2022. If you did not receive the link, please contact cinp2022-program@cinp.org.
Invited Speakers
Featured Oral Presentation
Oral Presentation
Poster Presentation
Important Technical Requirements
Best Practices

Call for Abstracts Now Closed

The Scientific Program Committee for the 33rd CINP World Congress of Neuropsychopharmacology (CINP 2022) thanks you for your submission of scientific abstracts.

Important Deadlines

• Abstract Submissions Open Week of 10 January 2022
• Abstract Submission Deadline Extended 6 March 2022
• Notification of Acceptance/Rejection 6 April 2022
• Deadline for Change of Title/Authorship 15 April 2022
• Presenting Author Registration Deadline 15 April 2022
  Abstract Submission Guidelines (click to expand)
  Presentation Types (click to expand)
  Submission Topics (click to expand)

Contact

If you have any questions regarding abstract submission, please contact the CINP Program Manager at  cinp2022-program[at]cinp.org

Call for Symposia Submission Now Closed

Notification of abstract acceptance emails have gone out to all Presenting Authors. If you have not been contacted, please reach out to cinp2022-program@cinp.org.
Symposia of 90 min duration integrate the latest advances in basic, clinical, and translational neuropsychopharmacology, biological psychiatry, drug development public policy issues relevant to mental health, mental illness, and treatment across the lifespan.

Four Speakers including the Chairperson should represent at least three different countries and four different institutions. It is recommended that at least two speakers should be CINP members. Symposia proposals that include female faculty and investigators who obtained their last degree in the last 10 years are greatly encouraged.

The individual who submits the symposium proposal via the submission process below must be the Chairperson of their proposed session.

Submitters can apply for no more than two symposia and speakers can agree to participate in no more than two proposals.

CINP 2022 Symposia will be reviewed and selected on a highly competitive basis by the International Scientific Programme Committee in October 2021. Notifications will be sent to all symposia submitters in November 2021.

Speakers in successful symposia will receive the following entitlements:

• Complimentary Congress registration
• 10000 pas en km
• 2 night’s accommodation at the Congress hotel
• Partial travel grant (to be reimbursed after the Congress; amount to be confirmed nearer the time)

Important Deadlines

• Symposia Submission Deadline 10 October 2021 (23:59 GMT+8)
• Notification of Submission Acceptance 8 November 2021
• Deadline for Change of Title/Authorship 10 October 2021
  Submission Guidelines (click to expand)
  Submission Affirmation (click to expand)
  Review Criteria (click to expand)
  Submission Topics (click to expand)

Contact

For questions regarding the symposia submission, please contact CINP Program Manager at  cinp2022-program[at]cinp.org

Stay tuned for more information on upcoming Congresses hosted by the International College of Neuropsychopharmacology (CINP).

CONGRESS SECRETARIAT
International Conference Services LTD (ICS)
#710-1201 West Pender Street
Vancouver, BC, Canada V6E 2V2
Phone: [+1] 604-681-2153
Email: cinp-congress@cinp.org
Web: www.icsevents.com

Registration

In-Person Registration

Registration for In-Person Attendance Is Now Closed

Please note that in-person registration is only open to residents of Taiwan.
For non residents of Taiwan, please click HERE to register as a virtual attendee.

Residents of Taiwan who wish to attend the Congress in-person in Taipei, please visit the TSBPN website*. The in-person registration fee includes access to the live Virtual Congress and on-demand content up to 15 September 2022.

For inquiries regarding the in-person registration, please contact TSBPN at tsbpn2002@gmail.com.

Conference Venue
CINP 2022 will be held at Chang Yung-Fa Foundation’s International Convention Center.

Address: No.11, Zhongshan S. Rd., Taipei City 10048, Taiwan (R.O.C.)

CHANG YUNG-FA FOUNDATION International Convention Center is located on Zhongshan South Road, an easily accessible thoroughfare. The building faces the Ketagalan Boulevard and is close to the National Taiwan University Hospital and Liberty Square (Chiang Kai-shek Memorial Hall). It is a 5min walk from MRT National Taiwan University Hospital Station and a 5min drive from Taipei Main Station.

Virtual Registration

Registration for CINP 2022 Virtual Library Now Closed

Virtual Library Registration Rates
[wpdatatable id=2]
Virtual Library Access Registration fee includes:

Access to On-Demand Content during the Congress and up to 15 September 2022
Eligibility for CINP Member Registration Fee
All CINP Members in good standing. Membership number will be required during the online registration process. If you do not know your membership number, please contact info@cinp.org.
Eligibility for Student/Trainee and Young Scientist Registration Fee
Proof of Status is required during the online registration process.
Student/Trainee - Please provide an official copy of your student card with photo or an official letter on your institution’s/organization’s letterhead that indicates proof of status as a Student or Trainee for 2022.

Young Scientist – Please provide an official copy of the last degree earned within the past 10 years.

If you are also a CINP Member, you will be required to provide your CINP membership number. If you do not know your membership number, please contact info@cinp.org.

Eligibility for Low and Lower-Middle Income Country Registration Fee
Residents of a country classified as “Low-Income” or “Lower-Middle Income” by the World Bank Classification as of 1 July 2021.
Group Registration
For groups of 10 or more registrations, please contact CINP2022-registration@cinp.org for assistance.
Cancellation Policy
Registration fees are non-refundable; however, transfer of your registration to another person is acceptable. Please email CINP2022-registration@cinp.org. Deadline to transfer your registration is 20 May 2022.
Registration Confirmation
Please check your email inbox for the Registration Confirmation. If not received, please check your spam folder before contacting CINP2022-registration@cinp.org for assistance.
Registration Contact
For any CINP 2022 registration questions, please contact the Registration Manager at CINP2022-registration@cinp.org.

Sponsorship & Exhibit

Interested in sponsoring or exhibiting at the 2022 CINP World Congress?

The Congress is pleased to offer a variety of opportunities, including but not limited to:

• Knowledge exchange opportunities: Product theater, Meet the expert session, etc.
• Exhibit space
• Digital and printed advertising opportunities
• Awards Support
• Registration bulk special rates
• Marketing opportunities; Delegate bag, Mobile app, etc.
• many more…

Statistics on past CINP Congresses (click to expand)

Past Event Attendance
Year Venue Attendance
2022 Taipei, Taiwan 1,500 exp.
2021 Virtual World Congress 743
2019 Athens, Greece 548
2018 Vienna, Austria 1,118
2016 Seoul, Republic of Korea 2,000
2014 Vancouver, Canada
Demographics & Statistics
Regional statistics from past CINP editions:
CINP 2022 (Taipei, Taiwan) CINP 2021 Virtual World Congress CINP 2019 (Athens, Greece) CINP 2018 (Vienna, Austria) CINP 2016 (Seoul, Republic of Korea)
60% Asia
20% Europe
10% North America
10% Others
(Exp.)
65% Asia
20% Europe
13% North America
1% South America
1% Africa
61% Europe
19% Asia
14% North America
3% Oceania
2% Africa
1% South America
Top 5 countries
Japan
USA
United Kingdom
Germany
Austria
65% Asia
15% Europe
10% North America
10% Others
Category statistics from CINP 2021:
Psychiatrist 31%
MD 16%
Basic Researcher 14%
Clinical Researcher 12%
Pharmacologist 7%
Other 6%
Biologist 4%
Psychologist 3%
None 2%
Child Psychiatrist 2%
Neurologist 1%
Forensic Psychiatrist 1%

CINP 2022 is an excellent opportunity to interact with (click to expand)

• Psychiatrist
• Basic Researcher
• Clinical Researcher
• Pharmacologist
• Biologist
• Psychologist
• Child Psychiatrist
• Neurologist
• Forensic Psychiatrist
• Neuroscientists
• Professors
• Researchers
• Students
• Others

Breakdown of CINP Association (click to expand)

No. of Members: 542
Demographics
Europe 31%
Asia 25%
North America 35%
Oceania 4%
Central & South America 3%
Africa 1%
Area of Interest (Multiple Choice)
ffective disorder – Depression 63%
Schizophrenia 39%
Affective disorder – Bipolar 45%
Anxiety Disorders 40%
Addiction & Substance Abuse 30%
Genetics 22%
Dementias 20%
Attention deficit/Hyperactivity disorders 6%
Parkinson’s & other degenerative diseases 15%
Neurohormones 15%

Past Sponsors & Exhibitors (click to expand)

• Abbott
• Allergan
• Alvogen
• Asian College NP
• AstraZeneca
• Biopac
• Borying Pharma
• Brainsway
• Cambridge Cognition
• Eisai
• Eli Lilly and Company
• EVER Neuro Pharma
• GlasxoSmithKline
• Handok Pharm
• Hanmi Pharm
• Janssen Pharmaceutical
• Karger Publishers
• Lundbeck
• MSD
• Myung In Pharma
• Otsuka Pharmaceutical
• Europe
• Oxford University Press
• Pfizer
• Roche
• Sage
• Sandoz
• Stoelting
• Sumitomo Dainippon
• Pharma
• Sunovion Pharmaceuticals
• Europe
• Suntory
• Takeda
• TEVA
• Wiley
• Wisepress Medical Bookshop

Contact

Please contact our Sponsorship and Exhibit Sales Managers to start discussing how you would like to support, and be involved in CINP 2022.

Sponsorship & Exhibit Sales Manager
Mrs. Tess Brown
sponsorship at cinp.org
Tess’s T: [+1] 604-681-2153 ext 176
Congress Secretariat
International Conference Services Ltd. (ICS)
Suite 710, 1201 West Pender Street
Vancouver, BC, V6E 2V2
Canada

Industry-Satellite Symposia

The following industry-supported symposia are organized by sponsors of the 33rd CINP World Congress of Neuropharmacology and will be available during the 2022 Live Days. Click on the tabs below to read more.

Industry Supported Symposia

Anxiety Symptoms in Depression: Contemporary Treatment Approaches

Agenda:
Introduction (5 mins)
The Challenge Anxiety Symptoms Treatment in Major Depressive Disorder (15 mins)
Evidence-based Pharmacotherapy of Anxiety Symptoms in Major Depressive Disorder (15 mins)
What do Patient want in the Treatment of Major Depressive Disorder? (Taiwan’s Tailor Survey) (15 mins)
Discussion and Closing (5 mins)
Chairman:
Professor Tung-Ping Su
Cheng Hsin General Hospital, Taiwan (R.O.C.)
Speakers:
Professor Dan J. Stein (Psychiatrist)
University of Cape Town, South Africa
Professor Malcolm Hopwood, (Prof of Psychiatry)
Albert Road Clinic, Australia
Professor Chia-Ming Chang
Chang Gung Memorial Hospital, Taiwan (R.O.C.)

ASPIRE to Improve the Management of MDD with Suicidal Ideation

Brief Description: This Janssen Asia Pacific symposium at the upcoming 33rd CINP Hybrid World Congress of Neuropsychopharmacology is one you would not want to miss! Presentations will shed light on the role of novel rapid-acting antidepressants in the management of major depressive disorder (MDD) with suicidal ideation (MDSI), a condition that represents a particularly vulnerable and hard-to-treat patient population which requires urgent treatment, and where current routine standard of care medications are inadequate. Our distinguished speakers will also share on their real-world experience, and discuss practicalities with the management of MDSI.
Agenda:

Opening remarks and introduction (5 mins)
A new era in the management of MDD with suicidal ideation (30 mins)
Management of MDD with suicidal ideation in Asia (15 mins)
Q&A; (10 mins)
Chairman:
Prof Cheng-Ta LI - Taiwan
National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taipei, Taiwan
Speaker:
Prof Bernhard BAUNE - Germany
University Hospital of Psychiatry and Psychotherapy, University of Münster, Germany

Industry Showcase Session

The 33rd CINP World Congress of Neuropharmacology offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of neuropharmacology. The 33rd CINP World Congress of Neuropharmacology would like to thank the following companies for their support:

SHOWCASE THEATER SESSION

Session title: Cerevel Therapeutics Pipeline Overview

Session date and time: Thursday, June 9th, 10:45 - 11:00am (GMT+8)

Session brief description: Cerevel Therapeutics is advancing a broad and diverse neuroscience pipeline of small molecule therapies to address significant unmet medical needs and limited treatment options for patients suffering from some of the most prevalent neuroscience diseases. Dr. Takahashi will give an overview of our clinical pipeline comprised of multiple therapeutic candidates that have the potential to achieve optimal therapeutic activity while minimizing the unintended side effects of currently available therapies.

Speaker: Koji Takahashi, PhD. Sr. Director Medical Affairs, Cerevel Therapeutics, USA.

Awards Support

The 33rd CINP World Congress of Neuropharmacology offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of neuropharmacology. The 33rd CINP World Congress of Neuropharmacology would like to thank Sumitomo Pharma Co. Ltd & Sunovion Pharmaceuticals Inc for sponsoring these awards:

• SUMITOMO/SUNOVION Brain Health Basic Research Award
• SUMITOMO/SUNOVION Brain Health Clinical Research Award